KDR and hereditary clear cell renal cell carcinoma: Tivozanib has been developed as an oral formulation and is currently considered a safe and tolerable VEGFR inhibitor for the treatment of renal cell carcinoma.13, 14, 15 The oral formulation containing tivozanib as the active ingredient has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of patients with advanced renal cell carcinoma.16